Regencell Bioscience Holdings annual current ratio
2020
2021
2022
2023
2024
2025
Regencell Bioscience Holdings Current Ratio Growth & History (RGC)
Regencell Bioscience Holdings's current ratio was 7.39 for fiscal 2025.
View full Regencell Bioscience Holdings company overviewRegencell Bioscience Holdings annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | 7.39 | −34.53 | −82.38% |
| 2024 | 2024-06-30 | 41.92 | 22.77 | +118.90% |
| 2023 | 2023-06-30 | 19.15 | −9.31 | −32.72% |
| 2022 | 2022-06-30 | 28.46 | 28.45 | +184590.45% |
| 2021 | 2021-06-30 | 0.02 | −0.11 | −87.40% |
| 2020 | 2020-06-30 | 0.12 | — | — |
Regencell Bioscience Holdings quarterly current ratio
Q4.20
Q4.21
Q4.22
Q4.23
Q4.24
Q4.25
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-06-30 | 7.39 | −34.53 | −82.38% |
| Q4 2024 | 2024-06-30 | 41.92 | 22.77 | +118.90% |
| Q4 2023 | 2023-06-30 | 19.15 | −9.31 | −32.72% |
| Q4 2022 | 2022-06-30 | 28.46 | 28.45 | +184590.45% |
| Q4 2021 | 2021-06-30 | 0.02 | −0.11 | −87.40% |
| Q4 2020 | 2020-06-30 | 0.12 | — | — |
Regencell Bioscience Holdings current ratio trends
Over the last five fiscal years, Regencell Bioscience Holdings's current ratio increased from 0.12 to 7.39, a change of 7.27. The latest reported quarter, Q4 2025, shows 7.39.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regencell Bioscience Holdings source filings ↗